ATA Guidelines Tools

Anaplastic Thyroid Cancer ATA 2021

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1441026

Contents of this Issue

Navigation

Page 9 of 27

Diagnosis 10 Table 2. Panel of Routine Immunohistochemical Markers for the Evaluation of Suspected Anaplastic Thyroid Cancer and Expected Results Compared to Other Tumor Types IHC marker DTC PDTC ATC MTC SCC Lymphoma Pan-cytokeratins +++ +++ +++/− +++ +++ − yroglobulin +++ +/− − − − − yroid-transcription factor 1 +++ +/− −/+ +/− − − BRAF V600E +/− −/+ −/+ − − − PAX8 +++ +++ +/− +/− − +/− a Ki-67 b <5% 5–30% >30% <20% >30% variable Chromogranin − − − +++ − − Calcitonin − − − +++/− − − CEA − − − +++ − − p53 −(rare+) −/+ +/− − +/− +/− CD45, other lymphoid markers − − − − − +++ a PAX8 antibodies can cross react with PAX5, which is expressed in lymphoid cells. b Percentage of nuclei positive for Ki-67. + indicates relative positive staining, − indicates negative staining, +/− indicates variable positivity.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Anaplastic Thyroid Cancer ATA 2021